Free Trial

BioLife Solutions (BLFS) Stock Price, News & Analysis

BioLife Solutions logo
$23.26 +0.51 (+2.24%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$23.68 +0.41 (+1.78%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioLife Solutions Stock (NASDAQ:BLFS)

Key Stats

Today's Range
$22.48
$23.34
50-Day Range
$20.69
$25.27
52-Week Range
$18.70
$29.55
Volume
503,412 shs
Average Volume
420,684 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.17
Consensus Rating
Buy

Company Overview

BioLife Solutions Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

BLFS MarketRank™: 

BioLife Solutions scored higher than 62% of companies evaluated by MarketBeat, and ranked 374th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioLife Solutions has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioLife Solutions' stock forecast and price target.
  • Earnings Growth

    Earnings for BioLife Solutions are expected to grow in the coming year, from ($0.30) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioLife Solutions is -80.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioLife Solutions is -80.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioLife Solutions has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about BioLife Solutions' valuation and earnings.
  • Percentage of Shares Shorted

    9.39% of the float of BioLife Solutions has been sold short.
  • Short Interest Ratio / Days to Cover

    BioLife Solutions has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in BioLife Solutions has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioLife Solutions does not currently pay a dividend.

  • Dividend Growth

    BioLife Solutions does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.39% of the float of BioLife Solutions has been sold short.
  • Short Interest Ratio / Days to Cover

    BioLife Solutions has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in BioLife Solutions has recently decreased by 6.84%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioLife Solutions has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BioLife Solutions this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,965,366.00 in company stock.

  • Percentage Held by Insiders

    Only 2.20% of the stock of BioLife Solutions is held by insiders.

  • Percentage Held by Institutions

    93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioLife Solutions' insider trading history.
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

Trump's ticking time bomb
A looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House document might be the real trigger. One market expert who predicted major collapses in 2008 is now warning of a second, far more explosive directive tied to America’s most vital resource. If he’s right, it could set off a financial shock unlike anything we’ve seen in decades.
See More Headlines

BLFS Stock Analysis - Frequently Asked Questions

BioLife Solutions' stock was trading at $25.96 at the start of the year. Since then, BLFS shares have decreased by 10.4% and is now trading at $23.26.

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, May, 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The medical equipment provider had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative trailing twelve-month return on equity of 0.66%.
Read the conference call transcript
.

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLife Solutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
5/08/2025
Today
7/06/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:BLFS
Employees
440
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.17
High Stock Price Target
$33.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+34.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.18 million
Pretax Margin
-8.22%

Debt

Sales & Book Value

Annual Sales
$82.25 million
Cash Flow
$0.12 per share
Price / Cash Flow
186.43
Book Value
$7.52 per share
Price / Book
3.09

Miscellaneous

Free Float
46,455,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
1.79

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:BLFS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners